Cheaper CAR-T therapy could expand access for lymphoma patients
NCT ID NCT07524816
First seen Apr 23, 2026 · Last updated Apr 23, 2026
Summary
This study is testing a lower-cost, academic version of CAR-T cell therapy for adults with relapsed or refractory large B-cell lymphoma. The goal is to see if this approach is safe and effective, while making treatment more affordable and available. Participants receive their own immune cells modified to attack cancer, and researchers will monitor response and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NN Alexandrov National Cancer Centre of Belarus
RECRUITINGLyasny, Minsk Oblast, 223040, Belarus
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.